procarbazine has been researched along with Cancer of Skin in 28 studies
Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose-effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones." | 9.10 | Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. ( Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D, 2002) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 9.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Forty-three patients with measurable disseminated cutaneous malignant melanoma, stages III-IV, and without previous cytotoxic chemotherapy or immunotherapy, were randomly allocated from 30 June 1980 to 30 November 1984, to receive either a schedule of procarbazine (100 mg/m2 p." | 9.06 | Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1986) |
| "Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1." | 7.67 | Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984) |
| "Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine." | 7.67 | Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 7.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine." | 7.66 | Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980) |
| "The aim of this randomized four-arm phase III study was to evaluate whether there is a difference in activity between regimens containing dacarbazine and regimens without dacarbazine in metastatic melanoma, whether there is a dose-effect relationship for dacarbazine, and whether non-dacarbazine-containing aggressive regimens are in any way superior to non-aggressive ones." | 5.10 | Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study. ( Babovic, N; Jelić, S; Kovcin, V; Milanovic, N; Milicevic, N; Popov, I; Radosavljevic, D, 2002) |
| "40 patients with symptomatic metastatic melanoma were treated with procarbazine, vincristine and lomustine (POC)." | 5.07 | Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma. ( Evans, BD; Harvey, VJ; Mak, D; Melville, P; Mitchell, PL; Samuel, LM; Thompson, PI, 1994) |
| "Forty-three patients with measurable disseminated cutaneous malignant melanoma, stages III-IV, and without previous cytotoxic chemotherapy or immunotherapy, were randomly allocated from 30 June 1980 to 30 November 1984, to receive either a schedule of procarbazine (100 mg/m2 p." | 5.06 | Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1986) |
| "Forty-four consecutive ambulatory patients (24 male, 20 female; median age, 56 years [range, 21-76]) with evaluable disseminated malignant melanoma (stages III/IV) were entered in this study from October 1, 1975, to July 21, 1980 (last follow-up, October 31, 1983); they were treated with procarbazine (100 mg/,m2 orally; maximum dose, 150 mg) on Days 1-10, vincristine (1." | 3.67 | Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up. ( Carmo-Pereira, J; Costa, FO; Henriques, E, 1984) |
| "Sixty-five previously untreated patients with metastatic malignant melanoma were treated with lomustine, vincristine, and procarbazine." | 3.67 | Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma. ( Bodurtha, A; Iscoe, N; Paterson, A; Quirt, I; Russell, J; Shelley, W; Young, V, 1985) |
| "Twenty-one patients with tumor stage mycosis fungoides (MF) with or without lymph node (LN) involvement, were treated with total skin electron beam irradiation (TSEB) followed by six monthly cycles of systemic chemotherapy (CT) of either mechlorethamine (HN2) or cyclophosphamide (CTX) with vincristine (VCR), procarbazine, and prednisone (PRD) (COPP or MOPP)." | 3.67 | Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up. ( Baron, JM; Griem, ML; Griem, SF; Hallahan, DE; Lorincz, AL; Medenica, M; Soltani, K, 1988) |
| "Fourteen consecutive melanoma patients with evaluable metastatic disease were treated with combination chemotherapy including procarbazine, vincristine and lomustine (POC)." | 3.67 | Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC). ( Ardizzoni, A; Grimaldi, A; Repetto, L; Rosso, R; Sertoli, MR, 1987) |
| "Thirty patients with disseminated cutaneous malignant melanoma were treated with a three-drug cytotoxic chemotherapy program consisting of CCNU, procarbazine, and vincristine." | 3.66 | Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup. ( Carmo-Pereira, J; Costa, FO; Henriques, E; Pimentel, P, 1980) |
| "Procarbazine was ineffective." | 1.28 | The chemotherapeutic response of a murine (VM) model of human glioma. ( Bradford, R; Darling, JL; Thomas, DG, 1990) |
| "Skin involvement with Hodgkin's disease is rare." | 1.28 | Cutaneous Hodgkin's disease in a patient with human immunodeficiency virus infection. ( Jacobs, SR; Shaw, MT, 1989) |
| "Diagnosis and therapy of malignant lymphoma of the skin were reviewed." | 1.27 | [Malignant lymphoma of the skin]. ( Miyamoto, H; Nakajima, H, 1985) |
| "We present a case of Hodgkin's disease and extensive skin infiltration with a favorable outcome." | 1.26 | Skin infiltration in Hodgkin's disease. ( Abt, AB; Gordon, RA; Lookingbill, DP, 1980) |
| "Despite the dramatic response of Hodgkin's disease to intensive chemotherapy, the skin lesion was rapidly transformed into squamous cell carcinoma in 10 weeks." | 1.26 | Rapid development of keratoacanthoma and accelerated transformation into squamous cell carcinoma of the skin: a mutagenic effect of polychemotherapy in a patient with Hodgkin's disease? ( Poleksic, S; Yeung, KY, 1978) |
| "Kaposi sarcoma is a rare disorder, usually controlled with conservative localized treatment." | 1.25 | Chemotherapy for advanced Kaposi sarcoma. ( Campos, LT; Lanzotti, VJ; Samuels, ML; Sinkovics, JG, 1975) |
| "Azathioprine was best tolerated, but gave only medium results whereas procarbazine, as a very potent drug, had the highest rate of side effects (especially depression of bone marrow, infections, gastrointestinal manifestations etc." | 1.25 | [Side effects in immunosuppressive therapy]. ( Thumb, N, 1975) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 24 (85.71) | 18.7374 |
| 1990's | 2 (7.14) | 18.2507 |
| 2000's | 2 (7.14) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Morbidini-Gaffney, S | 1 |
| Alpert, TE | 1 |
| Hatoum, GF | 1 |
| Sagerman, RH | 1 |
| Stragand, JJ | 1 |
| Drewinko, B | 1 |
| Barlogie, B | 1 |
| Papadopoulous, N | 1 |
| White, RA | 1 |
| Carmo-Pereira, J | 3 |
| Costa, FO | 3 |
| Henriques, E | 3 |
| Fodstad, O | 1 |
| Aass, N | 1 |
| Pihl, A | 1 |
| Pimentel, P | 1 |
| Gordon, RA | 1 |
| Lookingbill, DP | 1 |
| Abt, AB | 1 |
| Samuel, LM | 1 |
| Harvey, VJ | 1 |
| Mitchell, PL | 1 |
| Thompson, PI | 1 |
| Mak, D | 1 |
| Melville, P | 1 |
| Evans, BD | 1 |
| Jelić, S | 1 |
| Babovic, N | 1 |
| Kovcin, V | 1 |
| Milicevic, N | 1 |
| Milanovic, N | 1 |
| Popov, I | 1 |
| Radosavljevic, D | 1 |
| Lanzotti, VJ | 1 |
| Campos, LT | 1 |
| Sinkovics, JG | 1 |
| Samuels, ML | 1 |
| Bitran, JD | 1 |
| Desser, RK | 1 |
| DeMeester, TR | 1 |
| Colman, M | 1 |
| Evans, R | 1 |
| Billings, A | 1 |
| Griem, M | 1 |
| Rubenstein, L | 1 |
| Shapiro, C | 1 |
| Golomb, HM | 1 |
| Kolarić, K | 1 |
| Malenica, B | 1 |
| Roth, A | 1 |
| Poleksic, S | 1 |
| Yeung, KY | 1 |
| de Kreek, EJ | 1 |
| Sybesma, HB | 1 |
| Van Dyk, JJ | 1 |
| Falkson, G | 1 |
| Thumb, N | 1 |
| Bradford, R | 1 |
| Darling, JL | 1 |
| Thomas, DG | 1 |
| Shaw, MT | 1 |
| Jacobs, SR | 1 |
| Shelley, W | 1 |
| Quirt, I | 1 |
| Bodurtha, A | 1 |
| Iscoe, N | 1 |
| Russell, J | 1 |
| Paterson, A | 1 |
| Young, V | 1 |
| Hallahan, DE | 1 |
| Griem, ML | 1 |
| Griem, SF | 1 |
| Medenica, M | 1 |
| Soltani, K | 1 |
| Lorincz, AL | 1 |
| Baron, JM | 1 |
| Repetto, L | 1 |
| Grimaldi, A | 1 |
| Ardizzoni, A | 1 |
| Sertoli, MR | 1 |
| Rosso, R | 1 |
| Nakajima, H | 1 |
| Miyamoto, H | 1 |
| Dobrek, Z | 1 |
| Dantzig, PI | 1 |
| Gleichmann, E | 1 |
| Gleichmann, H | 1 |
| Moschella, SL | 1 |
| Luce, JK | 1 |
| Garrie, SA | 1 |
| Hirsch, P | 1 |
| Levan, N | 1 |
4 reviews available for procarbazine and Cancer of Skin
| Article | Year |
|---|---|
Immunosuppressive and cytotoxic drugs in dermatology.
Topics: Animals; Antineoplastic Agents; Azathioprine; Azauridine; Bleomycin; Chlorambucil; Cyclophosphamide; | 1974 |
Immunosuppression and neoplasia. II. Is deficient immunesurveillance the only mechanism by which immunosuppression promotes neoplasia? A speculative review.
Topics: Animals; Animals, Newborn; Antilymphocyte Serum; Antimetabolites; Azathioprine; Carcinogens; Cell Di | 1973 |
The present status of chemotherapy in dermatology.
Topics: Anti-Bacterial Agents; Antineoplastic Agents; Azathioprine; Azauridine; Chemotherapy, Cancer, Region | 1972 |
Chemotherapy of malignant melanoma.
Topics: Alkylating Agents; Amides; Animals; Antigen-Antibody Reactions; Antimetabolites; Antineoplastic Agen | 1972 |
4 trials available for procarbazine and Cancer of Skin
| Article | Year |
|---|---|
Phase II trial of procarbazine, vincristine and lomustine (POC) chemotherapy in metastatic cutaneous malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Humans; Lomustine; Male; Melano | 1994 |
Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Carmustine; Dacarbazine; Dose-Response | 2002 |
Cytotoxic chemotherapy of disseminated cutaneous malignant melanoma--a prospective and randomized clinical trial of procarbazine, vindesine and lomustine versus procarbazine, DTIC and lomustine.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Dacarbazine; Drug Evaluation; Female; H | 1986 |
[Clinical trials of chemotherapy and chemoimmunotherapy of malignant melanoma with unfavorable prognosis after surgical treatment].
Topics: Adjuvants, Immunologic; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Clinical | 1985 |
20 other studies available for procarbazine and Cancer of Skin
| Article | Year |
|---|---|
Benign pleural schwannoma secondary to radiotherapy for Hodgkin disease.
Topics: Adolescent; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Carcinoma, Basal Cell; Combin | 2005 |
Serial analysis of melanoma growth kinetics in a patient receiving bleomycin and procarbazine therapy: comparison of tumor volume, flow cytometry, and thymidine labeling techniques.
Topics: Autoradiography; Bleomycin; Cell Division; DNA, Neoplasm; Female; Flow Cytometry; Humans; Melanoma; | 1982 |
Combination cytotoxic chemotherapy with procarbazine, vincristine, and lomustine (POC) in disseminated malignant melanoma: 8 years' follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Follow-Up Studies; Humans; Lomu | 1984 |
Response to chemotherapy of human, malignant melanoma xenografts in athymic, nude mice.
Topics: Abrin; Animals; Antineoplastic Agents; Dacarbazine; Humans; Lomustine; Melanoma; Mice; Mice, Nude; N | 1980 |
Combination cytotoxic chemotherapy with CCNU, procarbazine, and vincristine in disseminated cutaneous malignant melanoma: 3 years, followup.
Topics: Adult; Aged; Female; Follow-Up Studies; Humans; Leukopenia; Lomustine; Male; Melanoma; Middle Aged; | 1980 |
Skin infiltration in Hodgkin's disease.
Topics: Adult; Drug Therapy, Combination; Hodgkin Disease; Humans; Male; Mechlorethamine; Prednisone; Procar | 1980 |
Chemotherapy for advanced Kaposi sarcoma.
Topics: Aged; Bleomycin; Dacarbazine; Dactinomycin; Doxorubicin; Humans; Male; Mechlorethamine; Middle Aged; | 1975 |
Cyclophosphamide, adriamycin, methotrexate, and procarbazine (CAMP)--effective four-drug combination chemotherapy for metastatic non-oat cell bronchogenic carcinoma.
Topics: Adenocarcinoma; Adenocarcinoma, Bronchiolo-Alveolar; Adult; Aged; Bone Neoplasms; Brain Neoplasms; C | 1976 |
A preliminary report of a pilot trial in adjuvant chemotherapy of primary melanoma.
Topics: Antineoplastic Agents; BCG Vaccine; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Hu | 1979 |
Rapid development of keratoacanthoma and accelerated transformation into squamous cell carcinoma of the skin: a mutagenic effect of polychemotherapy in a patient with Hodgkin's disease?
Topics: Antineoplastic Agents; Carcinoma, Squamous Cell; Drug Therapy, Combination; Hodgkin Disease; Humans; | 1978 |
[From tumors to scales].
Topics: Agranulocytosis; Humans; Immunologic Deficiency Syndromes; Leg Ulcer; Leukopenia; Male; Mechloretham | 1975 |
A clinical trial of procarbazine plus vincristine plus bis-chloroethyl-nitrosourea plus imidazole carboxamide dimethyl triazeno in metastatic malignant melanoma.
Topics: Adult; Aged; Carmustine; Dacarbazine; Drug Therapy, Combination; Female; Humans; Liver Neoplasms; Lu | 1975 |
[Side effects in immunosuppressive therapy].
Topics: Alopecia; Amenorrhea; Anemia; Azathioprine; Bacterial Infections; Chlorambucil; Female; Humans; Immu | 1975 |
The chemotherapeutic response of a murine (VM) model of human glioma.
Topics: Animals; Astrocytoma; Brain Neoplasms; Carmustine; Disease Models, Animal; Lomustine; Mice; Mice, In | 1990 |
Cutaneous Hodgkin's disease in a patient with human immunodeficiency virus infection.
Topics: Acquired Immunodeficiency Syndrome; Adult; Antineoplastic Combined Chemotherapy Protocols; Biopsy; H | 1989 |
Lomustine, vincristine, and procarbazine in the treatment of metastatic malignant melanoma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Female; Hematologic Diseases; Humans; L | 1985 |
Combined modality therapy for tumor stage mycosis fungoides: results of a 10-year follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophospha | 1988 |
Metastatic malignant melanoma treated with procarbazine, vincristine and lomustine (POC).
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Bone Neoplasms; Brain Neoplasms; Female | 1987 |
[Malignant lymphoma of the skin].
Topics: Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclophosphamide; Diagnos | 1985 |
Granuloma annulare-like pattern in mycosis fungoides.
Topics: Biopsy; Granuloma; Humans; Male; Methotrexate; Microscopy, Electron; Middle Aged; Mycosis Fungoides; | 1972 |